Elisabetta Bonzano MD, PhD· @to_be_elizabeth · X·· 23 hours agoScore70
Body · original
📌 Proffered paper 2: Breast cancer, early and advanced stage
Results from KEYNOTE-B49: A phase 3, randomized, double-blind study of pembro vs placebo plus chemotherapy in pts with HR+/HER2- advanced breast cancer
✨@hoperugo
#ESMO26 🇪🇸 @OncoAlert #OncoAlertAF
55 views · 4 likes · 3 reposts · 0 replies
Conference abstracts
LBA51matched by Proffered paper 2: Breast cancer, early and advanced stage
Results from KEYNOTE-B49: A phase 3, randomized, double-blind study of pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (CT) in participants (pts) with HR+/HER2− advanced breast cancer (ABC)
https://esmocongress.esmo.orgSource: Elisabetta Bonzano MD, PhD · x.com